RxDoctor Payments Data

Vicente Vazquez, MD

Family Medicine · Riverside, CANPI 1861978371

Payments from drug & device makers

$7,533in general payments, 2019–2025

Across 407 payments — averaging $18.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$663
  • Otsuka America Pharmaceutical, Inc.$552
  • Bayer$546
  • Novo Nordisk$497
  • Boehringer Ingelheim$492
  • AstraZeneca$467
  • plus $4K from 34 others

What the payments were for

  • Food & beverage$7,533100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,533 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$121,256
Medicare patients
267
Services billed
1,217

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide104$102,999
JardianceEmpagliflozin74$100,241
EliquisApixaban67$84,395
KerendiaFinerenone38$48,332
JanuviaSitagliptin Phosphate30$38,538
MyrbetriqMirabegron31$28,401
XareltoRivaroxaban24$28,328
Diclofenac Sodium33$23,178
MounjaroTirzepatide20$22,010
RybelsusSemaglutide20$21,643
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$17,242
UbrelvyUbrogepant14$16,665
FarxigaDapagliflozin Propanediol22$15,706
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog17$14,138
QuliptaAtogepant11$13,081

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$497$124,642124 claims
Boehringer IngelheimJardiance, Stiolto Respimat$492$105,05185 claims
PfizerEliquis, Paxlovid$190$85,82478 claims
BayerKerendia$546$48,33238 claims
MerckJanuvia$166$38,53830 claims
AbbVieUbrelvy, Qulipta$663$29,74625 claims
Astellas Pharma US IncMyrbetriq$288$28,40131 claims
Lilly USA, LLCMounjaro$239$22,01020 claims
GSKTrelegy Ellipta$180$17,24215 claims
AstraZenecaFarxiga$467$15,70622 claims
Sanofi-aventis U.S. LLCLantus$24$1,96518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Riverside

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →